Medical Device News Magazine

Violet Defense Reports Effectiveness of UV Technology Unchanged After CDC Revises COVID-19 Guidance

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Violet Defense advises an April update from the Centers for Disease Control and Prevention (CDC) significantly changes the agency’s guidance on how they believe the COVID-19 virus is transmitted.

But UV light disinfection products, like the patented technology from Violet Defense, still effectively address its key pathogen transmission pathways.

SARS-CoV-2, the virus behind COVID-19, most often spreads through droplets found in the air, where traditional chemical cleaning products are ineffective at killing germs, although, the CDC still recommends frequent disinfection of high-touch surfaces in areas with high risk of transmission of COVID-19 or low levels of mask-wearing. Given this guidance, finding solutions that can easily address both air and surface disinfection is prudent.

Violet Defense, makers of commercial UV disinfection products, offers the only known Pulsed Xenon disinfection solution that can be installed for fully automatic disinfection. It provides reliable and continuous disinfection of any area, covering both the air and surfaces in 30-minute cycles. The technology is proven through third-party lab testing to effectively kill up to 99.9% of SARS-CoV-2, MRSA, Norovirus, E.coli, and Salmonella. Violet Defense also now offers a series of continuous UV air disinfection products from PURO Air aimed at HVAC systems, in-duct and in-room air disinfection even in occupied spaces.

“UV disinfection technology is an effective and affordable method to kill dangerous germs that are found both in the air and on surfaces and should be considered as part of a multi-layered disinfection strategy,” said Terrance Berland, Chief Executive Officer of Violet Defense. “Even after we move past the threat of COVID-19, germ-killing technology will be vital to protect busy public places such as schools, fire and police departments, museums, and other large venues where people regularly congregate. Moving forward, we fully expect that UV technology will be a particularly valuable investment to provide our world’s critical infrastructure with protection against the next outbreak or even our annual flu season,” Berland said.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”